About
Cbio develops next-generation T-cell therapies to treat late-stage solid cancers using its proprietary REVITA technology platform to create potent multitargeted immune cells that effectively target and kill cancer cells.
Explore Cbio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.